Nov 8 (Reuters) - Hikma Pharmaceuticals Plc said itexpects full-year revenue growth of 20 percent and raised itssales forecast for its generics unit as sales of antibioticdoxycycline continued to soar.
The drugmaker now expects full-year sales in its genericunit to be about $260 million.
The company, which makes and sells branded and genericdrugs, has raised its full-year revenue forecast three timesthis year and said in August that it expected revenue from itsgenerics unit to be about $230 million.
The U.S. Food and Drug Administration said in June thatthere was a scarcity of doxycycline - an antibiotic used in thetreatment of malaria and other infections - in the United Statesdue to domestic manufacturing issues, adding that an acuteshortage of substitutes was driving sales of the antibiotic. ()
Hikma shares closed at 1210 pence on the London StockExchange on Thursday.
Hikma Pharmaceuticals (HIK)
